Health Care Costs in People With Diabetes and Their Association With Glycemic Control and Kidney Function
暂无分享,去创建一个
Braden J. Manns | Doreen Rabi | Natasha Wiebe | Scott W. Klarenbach | Pietro Ravani | B. Hemmelgarn | B. Chui | B. Manns | S. Klarenbach | N. Wiebe | P. Ravani | F. Clement | K. McBrien | D. Rabi | Flora Au | Brenda Hemmelgarn | Fiona Clement | Kerry A. McBrien | Betty Chui | Flora Au
[1] Philip Jacobs,et al. The cost of major comorbidity in people with diabetes mellitus. , 2003, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.
[2] T. Gilmer,et al. Predictors of health care costs in adults with diabetes. , 2005, Diabetes care.
[3] A Fournier,et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. , 1994, The New England journal of medicine.
[4] J. Caro,et al. Cost of managing complications resulting from type 2 diabetes mellitus in Canada , 2003, BMC health services research.
[5] R. Rosenson,et al. Does microvascular disease predict macrovascular events in type 2 diabetes? , 2011, Atherosclerosis.
[6] S. Pohar,et al. Health care utilization and costs in Saskatchewan's registered Indian population with diabetes , 2007, BMC Health Services Research.
[7] J. Stockman,et al. A New Equation to Estimate Glomerular Filtration Rate , 2011 .
[8] Jonathan C Craig,et al. Role of blood pressure targets and specific antihypertensive agents used to prevent diabetic nephropathy and delay its progression. , 2006, Journal of the American Society of Nephrology : JASN.
[9] R. Holman,et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study , 2000, BMJ : British Medical Journal.
[10] E. Bonora,et al. Glomerular filtration rate, albuminuria and risk of cardiovascular and all-cause mortality in type 2 diabetic individuals. , 2010, Nutrition, metabolism, and cardiovascular diseases : NMCD.
[11] Janet E Hux,et al. Diabetes in Ontario: determination of prevalence and incidence using a validated administrative data algorithm. , 2002, Diabetes care.
[12] W. Manning,et al. The Cost to Health Plans of Poor Glycemic Control , 1997, Diabetes Care.
[13] M. Woodward,et al. Lowering blood pressure reduces renal events in type 2 diabetes. , 2009, Journal of the American Society of Nephrology : JASN.
[14] R. Bain,et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. , 1993, The New England journal of medicine.
[15] R. Stolk,et al. Insulin monotherapy versus combinations of insulin with oral hypoglycaemic agents in patients with type 2 diabetes mellitus. , 2004, The Cochrane database of systematic reviews.
[16] Kdoqi Disclaimer. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[17] C. Mackenzie,et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.
[18] C. Lawton. Highlights of the 2003 Clinical Practice Guidelines for the prevention and management of diabetes in Canada. , 2004, CANNT journal = Journal ACITN.
[19] A. Wajda,et al. Incidence and Prevalence of Diabetes in Manitoba, 1986–1991 , 1996, Diabetes Care.
[20] H. Quan,et al. Coding Algorithms for Defining Comorbidities in ICD-9-CM and ICD-10 Administrative Data , 2005, Medical care.
[21] R. Poveda,et al. Goodpasture syndrome during the course of a Schönlein-Henoch purpura. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[22] H. Parving,et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. , 2001, The New England journal of medicine.
[23] B. Kasiske,et al. Effect of Antihypertensive Therapy on the Kidney in Patients with Diabetes: A Meta-Regression Analysis , 1993, Annals of Internal Medicine.
[24] J. Caro,et al. Economic Outcomes Associated with Microvascular Complications of Type 2 Diabetes Mellitus , 2012, PharmacoEconomics.
[25] B. Wells,et al. Health Care and Productivity Costs Associated With Diabetic Patients With Macrovascular Comorbid Conditions , 2009, Diabetes Care.
[26] Janet E Hux,et al. Trends in diabetes prevalence, incidence, and mortality in Ontario, Canada 1995–2005: a population-based study , 2007, The Lancet.
[27] Morton B. Brown,et al. The direct medical cost of type 2 diabetes. , 2003, Diabetes care.
[28] C. Truman,et al. Influence of aboriginal and socioeconomic status on birth outcome and maternal morbidity. , 2002, Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC.
[29] M. Aagren,et al. Association between glycemic control and short-term healthcare costs among commercially insured diabetes patients in the United States , 2011, Journal of medical economics.
[30] N. Duan. Smearing Estimate: A Nonparametric Retransformation Method , 1983 .
[31] E H Wagner,et al. Effect of improved glycemic control on health care costs and utilization. , 2001, JAMA.
[32] Chris Cameron,et al. Second-line therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a systematic review and mixed-treatment comparison meta-analysis , 2011, Open medicine : a peer-reviewed, independent, open-access journal.
[33] E. Lewis,et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. , 2001, The New England journal of medicine.
[34] R. Bain,et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. , 1993 .
[35] K. Secnik,et al. The association between diabetes related medical costs and glycemic control: A retrospective analysis , 2006, Cost effectiveness and resource allocation : C/E.
[36] C. Schmid,et al. A new equation to estimate glomerular filtration rate. , 2009, Annals of internal medicine.
[37] Ethan M Balk,et al. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[38] B. Brenner,et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. , 2001, The New England journal of medicine.
[39] J. Stoker,et al. The Department of Health and Human Services. , 1999, Home healthcare nurse.
[40] Y. Jang,et al. Standards of Medical Care in Diabetes-2010 by the American Diabetes Association: Prevention and Management of Cardiovascular Disease , 2010 .
[41] Anushka Patel,et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial , 2007, The Lancet.
[42] Jennifer MacRae,et al. Overview of the Alberta Kidney Disease Network , 2009, BMC nephrology.
[43] V. Basevi,et al. Standards of Medical Care in Diabetes—2012 , 2011, Diabetes Care.